Introduction
Human African trypanosomiasis (HAT), also known as sleeping sickness, is caused by two parasites, Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense, transmitted by tsetse flies and is generally fatal if not treated. The Gambiense form of the disease (gHAT) accounts for over 90% of cases.1 There were three major gHAT epidemics in the 20th century, the most recent occurring in the 1990s when over 35 000 cases were reported in some years.2 This led to a concerted international effort, coordinated by the WHO, to bring the disease under control. These efforts brought the case numbers down to below 10 000 per year by 2009.3 In 2012, WHO targeted HAT for elimination as a public health problem by 2020,4 defined as fewer than 2000 new cases reported annually and a 90% reduction in the areas at moderate or higher risk compared with 2000–2004.5 The first target was reached in 2017 and has been sustained while the second target was narrowly missed.2 A new 2021–2030 roadmap has been published where gHAT is targeted for elimination of transmission.6
Historically, control of gHAT has primarily relied on the detection and treatment of human cases.7 However, the role of vector control in gHAT elimination efforts has assumed greater prominence in recent years following the development of a cost-effective vector control technology, ‘Tiny Targets’. Tiny targets are insecticide-impregnated screens comprising a blue panel and a black mesh panel; the colour attracts tsetse which takes up insecticide on contact and is subsequently killed. Tiny Targets are cheap, logistically easy to deploy and have been shown to reduce tsetse densities by >80%; modelling has demonstrated that a sustained 72% reduction of tsetse populations will stop HAT transmission.8–13 Analyses have shown that Tiny Target interventions significantly reduce the incidence of gHAT, thus demonstrating the value of adding vector control to screening and treatment efforts.9 11 14
Tiny Target implementation in gHAT endemic countries has taken place within the frame of international partnerships. For example, the Liverpool School of Tropical Medicine (LSTM) based in the UK has partnered with relevant national organisations in Cameroon, the Democratic Republic of Congo and Uganda in support of Tiny Target-based vector control programmes.12 13 15 International partnerships of this type can be highly successful with respect to the underlying disease control, prevention or elimination objective/s. As a case in point, Uganda received validation from WHO in 2022 that gHAT has been eliminated as a public health problem, driven in large part by international partnerships focused on supporting both case detection and treatment and vector control.16 17 International partnerships can also enhance vector control capacity and capability in less well capacitated partner countries,18 a foundation of the WHO’s global vector control response, 2017–2030.19 Despite this potential, there are few research-derived accounts in the published literature on how capacity strengthening components embedded within international vector control partnerships function or perform. Research of this type is needed to ensure capacity strengthening practices within such partnerships are optimised.
In this paper, we present findings from a qualitative study conducted in support of national capacity strengthening within the ‘Targeting Tsetse’ vector control project. Targeting Tsetse was an international partnership between LSTM and the Coordinating Office for Control of Trypanosomiasis in Uganda (COCTU). This partnership formally commenced in 2014 with the primary objective of implementing a Tiny Target programme in support of Uganda’s gHAT elimination goal. The partnership further supported national capacity strengthening in vector control operations through the provision of technical assistance, a ‘learn-by-doing’ implementation model and via a bespoke capacity strengthening action cycle (described further below). Overarching aims of these capacity strengthening activities were to ensure national partners were sufficiently capacitated to implement the Tiny Target programme as intended and to facilitate a shift towards greater national independence in tsetse control, that is, less reliance on international partners to implement tsetse control as needed. Our study had multiple objectives, including (1) identifying the capacity strengthening priorities of the Ugandan partners in the project; (2) exploring the project-specific capacity strengthening processes, experiences and outcomes; (3) informing future directions within the partnership and (4) deriving transferable lessons that may inform national capacity strengthening approaches within other partnership-based vector control programmes.
Capacity strengthening is often not defined when discussed in the literature and standardised definitions have not been widely agreed.20 However, contemporary descriptions typically refer to three levels of capacity strengthening, including the individual, the organisational and the societal (or national), emphasising a ‘whole system’ approach to capacity strengthening in the focal area.21 22 Terminology also varies with the phrasing ‘capacity strengthening’, ‘capacity building’ and ‘capacity development’ often used interchangeably,20 despite efforts to differentiate between the terms.23 Traditional notions of capacity strengthening have been critiqued in the Global Health literature on the grounds that they perpetuate assumptions of ‘Northern’ superiority over ‘Southern’ counterparts and/or Southern knowledge systems.24 As such, the notion of bidirectionality or multidirectionality in capacity strengthening which recognises all members of any partnership, irrespective of their respective location or existing capacities, gain new knowledge, skills or experience as a result of the partnership is increasingly promoted22; although recognising that within an equitable partnership, some members may require additional capacity strengthening support as compared with others. While our study focuses solely on the capacity strengthening process, experience and outcomes of Ugandan partners within a UK–Uganda partnership, we wholeheartedly recognise that the capacity gains were bidirectional. Our focus on the Ugandan partner experience within this paper is primarily informed by the explicit call from the WHO to build vector control capacity within the Global South19 and recognition that international, disease control and elimination partnerships of which the Tiny Target is just one of multiple examples can afford an excellent opportunity to do so if appropriately designed and delivered.